Short Interest in Biodexa Pharmaceuticals PLC Unsponsored ADR (NASDAQ:BDRX) Expands By 298.4%

Biodexa Pharmaceuticals PLC Unsponsored ADR (NASDAQ:BDRX) was the target of a large increase in short interest in the month of December. As of December 15th, there was short interest totaling 494,378 shares, an increase of 298.4% from the November 30th total of 124,098 shares. Based on an average trading volume of 3,356,723 shares, the short-interest ratio is presently 0.1 days. Approximately 80.0% of the company’s shares are short sold. Approximately 80.0% of the company’s shares are short sold. Based on an average trading volume of 3,356,723 shares, the short-interest ratio is presently 0.1 days.

Analyst Ratings Changes

Separately, Weiss Ratings reissued a “sell (e)” rating on shares of Biodexa Pharmaceuticals in a research report on Monday, December 15th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock has a consensus rating of “Sell”.

Biodexa Pharmaceuticals Stock Performance

Shares of BDRX stock opened at $2.86 on Friday. The firm has a fifty day simple moving average of $5.34 and a 200-day simple moving average of $6.90. Biodexa Pharmaceuticals has a twelve month low of $2.83 and a twelve month high of $92.00.

Biodexa Pharmaceuticals Company Profile

Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of Type 1 diabetes and rare/orphan cancers of the brain. Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes. The company is also developing MTX110, which is currently in Phase I studies for the treatment of diffuse intrinsic recurrent glioblastoma, diffuse midline glioma, and medulloblastoma; and MTD217, a program centered around a water-soluble drug formulation that can be easily infused or injected simultaneously, or sequentially, directly into the cancer microenvironment, currently under preclinical studies for the treatment of leptomeningeal disease.